Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy

Inclusion Criteria:

• Age ≥ 18 years old, regardless of gender.

• It is diagnosed as colorectal cancer by histopathology, TNM stage Ⅱ.

• Received radical resection of colorectal cancer (R0) within 12 weeks prior toenrollment.

• Not receiving neoadjuvant therapy before surgery, and not receiving any adjuvanttherapy after surgery.

• ECOG score 0-2 points.

• According to the CSCO Colorectal Cancer Guidelines 2022, it meets the criteria forreceiving monotherapy adjuvant therapy with capecitabine.

• Clear consciousness, language expression or reading ability, able to communicatenormally, and cooperate in completing questionnaire assessments.

• Voluntarily join this study and sign an informed consent form.

Exclusion Criteria:

• Low rectal cancer (occurring within 12 centimeters from the anal margin)

• Combining medical history of other malignant tumors.

• Known to be allergic to the components of Huaier granules or avoid or use Huaiergranules with caution (only in the experimental group).

• Inability to take orally medication (experimental group, control group with oralmedication included in standard treatment plan).

• Pregnant or lactating women or planned pregnancy preparation.

• In the past one month, the subjects have received Huaier granules or traditionalChinese patent medicines and simple preparations with similar efficacy orindications to Huaier granules (such as compound cantharides capsules, cinobufacincapsules, Kangai injection, Pingxiao tablets, please refer to the instruction manualfor details).

• Refusal to cooperate with follow-up.

• Other reasons leading to the researcher's belief that it is not suitable toparticipate in this study.